Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 3011-3014

  Oppegard, Lisa M ^a   Streck, Kathryn R ^a   Rosen, Jonathan D ^b   Schwanz, Heidi A ^b   Drlica, Karl ^c   Kerns, Robert J ^b   Hiasa, Hiroshi ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHOXYPYRIDO[1,2 C]PYRIMIDINE 1,3 DIONE; 8 METHOXYFLUOROQUINOLONE; 8 METHOXYQUINAZOLINE 2,4 DIONE; 8 METHYLQUINAZOLINE 2,4 DIONE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GYRASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UIJR 1 048; UIJR 1 100; UING 5 207; UING 5 249; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; VIRUS PROTEIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; WILD TYPE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; ENZYME ACTIVATION; ESCHERICHIA COLI; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; STAPHYLOCOCCUS AUREUS; VIRAL PROTEINS;

EID: 77953780481     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00190-10     Document Type: Article

References (33)

1. Acar, J. F. 1997. Consequences of bacterial resistance to antibiotics in medical practice. Clin. Infect. Dis. 24(Suppl. 1):S17-S18.
2. Bird, P., E. Ellsworth, D. Nguyen, J. Sanchez, H. Showalter, R. Singh, M. Stier, T. Tran, B. Watson, and J. Yip. August 2006. 3-Aminoquinazolin-2,4-dione antibacterial agents. U.S. patent 7,094,780 B1.
3. Blanche, F., B. Cameron, F. X. Bernard, L. Maton, B. Manse, L. Ferrero, N. Ratet, C. Lecoq, A. Goniot, D. Bisch, and J. Crouzet. 1996. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob. Agents Chemother. 40:2714-2720.
4. Caeiro, J. P., and P. B. Iannini. 2003. Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity. Expert Rev. Anti Infect. Ther. 1:363-370.
5. Dong, Y., C. Xu, X. Zhao, J. Domagala, and K. Drlica. 1998. Fluoroquinolone action against mycobacteria: effects of C8 substituents on bacterial growth, survival, and resistance. Antimicrob. Agents Chemother. 42:2978-2984.
6. Drlica, K., H. Hiasa, R. J. Kerns, M. Malik, A. Mustaev, and X. Zhao. 2009. Quinolones: action and resistance updated. Curr. Top. Med. Chem. 9:981-998.
7. Ellsworth, E. L., and H. D. H. Showalter. June 2003. Antibacterial agents. U.S. patent 0114458 A1.
8. Ellsworth, E. L., T. Tran, H. H. Showalter, J. Sanchez, B. Watson, M. Stier, J. Domagala, S. Gracheck, E. Joannides, M. Shapiro, S. Dunham, D. Hanna, M. Huband, J. Gage, J. Bronstein, J. Liu, D. Nguyen, and R. Singh. 2006. 3-Aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. J. Med. Chem. 49:6435-6438.
9. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653.
10. Fischbach, M. A., and C. T. Walsh. 2009. Antibiotics for emerging pathogens. Science 325:1089-1093.
11. Fournier, B., X. Zhao, T. Lu, K. Drlica, and D. C. Hooper. 2000. Selective Targeting of Topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob. Agents Chemother. 44:2160-2165.
12. German, N., M. Malik, J. Rosen, K. Drlica, and R. J. Kerns. 2008. Use of gyrase resistance mutants to guide selection of 8-methoxyquinazoline-2,4-diones. Antimicrob. Agents Chemother. 52:3915-3921.
13. Hiasa, H. 2002. The Glu-84 of the ParC subunit plays critical roles in both topoisomerase IV-quinolone and topoisomerase IV-DNA interactions. Biochemistry 41:11779-11785.
14. Hiasa, H., R. J. DiGate, and K. J. Marians. 1994. Decatenating activity of Escherichia coli DNA gyrase and topoisomerases I and III during oriC and pBR322 DNA replication in vitro. J. Biol. Chem. 269:2093-2099.
15. Hiasa, H., and M. E. Shea. 2000. DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrasequinolone-DNA ternary complex. J. Biol. Chem. 275:34780-34786.
16. Hiasa, H., M. E. Shea, C. M. Richardson, and M. N. Gwynn. 2003. Staphylococcus aureus gyrase-quinolone-DNA ternary complexes fail to arrest replication fork progression in vitro: effects of salt on the DNA binding mode and the catalytic activity of Staphylococcus aureus gyrase. J. Biol. Chem. 278:8861-8868.
17. Horton, R. M., S. N. Ho, J. K. Pullen, H. D. Hunt, Z. Cai, and L. R. Pease. 1993. Gene splicing by overlap extension. Methods Enzymol. 217:270-279.
18. Huband, M. D., M. A. Cohen, M. Zurack, D. L. Hanna, L. A. Skerlos, M. C. Sulavik, G. W. Gibson, J. W. Gage, E. Ellsworth, M. A. Stier, and S. J. Gracheck. 2007. In vitro and in vivo activities of PD0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob. Agents Chemother. 51:1191-1201.
19. Ince, D., X. Zhang, L. C. Silver, and D. C. Hooper. 2002. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob. Agents Chemother. 46:3370-3380.
20. Khodursky, A. B., E. L. Zechiedrich, and N. R. Cozzarelli. 1995. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 92:11801-11805.
21. Kreuzer, K. N., and N. R. Cozzarelli. 1979. Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J. Bacteriol. 140:424-435.
22. Lu, T., X. Zhao, and K. Drlica. 1999. Gatifloxacin activity against quinoloneresistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activity by the C-8-methoxy group. Antimicrob. Agents Chemother. 43:2969-2974.
23. Okumura, R., T. Hirata, Y. Onodera, K. Hoshino, T. Otani, and T. Yamamoto. 2008. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 62:98-104.
24. Oppegard, L., B. Hamann, K. R. Streck, K. C. Ellis, H. Fieldler, A. B. Khodursky, and H. Hiasa. 2009. In vivo and in vitro patterns of the activity of simocyclinone D8, an angucyclineone antibiotic from Streptomyces antibioticus. Antimicrob. Agents Chemother. 53:2110-2119.
25. Pan, X.-S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471-474.
26. Pan, X. S., and L. M. Fisher. 1998. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2810-2816.
27. Pan, X.-S., K. A. Gould, and L. M. Fisher. 2009. Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV. Antimicrob. Agents Chemother. 53:3822-3831.
28. Peng, H., and K. J. Marians. 1993. Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. J. Biol. Chem. 268:24481-24490.
29. Peterson, L. R. 2005. Quinolone resistance in clinical practice: occurrence and importance, p. 119-137. In D. C. Hooper and J. S. Wolfson (ed.), Quinolone antimicrobial agents, 2nd ed. ASM Press, Washington, DC.
30. Rosen, J. D., N. German, and R. J. Kerns. 2009. Efficient synthesis of the 2-amino-6-chloro-4-cyclopropyl-7-fluoro-5-methoxy-pyrido[1,2-c]pyrimidine-1, 3-dione core ring system. Tetrahedron Lett. 50:785-789.
31. Strahilevitz, J., and D. C. Hooper. 2005. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob. Agents Chemother. 49:1949-1956.
32. Taubes, G. 2008. The bacteria fight back. Science 321:356-361.
33. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. U. S. A. 94:13991-13996.